R. Asola

2.4k total citations
16 papers, 697 citations indexed

About

R. Asola is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, R. Asola has authored 16 papers receiving a total of 697 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Cancer Research and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in R. Asola's work include Cancer Treatment and Pharmacology (9 papers), Breast Cancer Treatment Studies (8 papers) and HER2/EGFR in Cancer Research (4 papers). R. Asola is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Breast Cancer Treatment Studies (8 papers) and HER2/EGFR in Cancer Research (4 papers). R. Asola collaborates with scholars based in Finland, Sweden and Ireland. R. Asola's co-authors include Heikki Joensuu, Pirkko‐Liisa Kellokumpu‐Lehtinen, Taina Turpeenniemi‐Hujanen, R. Kokko, Petri Bono, Vesa Kataja, Mika Leinonen, Päivi Auvinen, Marjo Pajunen and Leena Helle and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

R. Asola

16 papers receiving 673 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. Asola Finland 9 522 281 215 198 61 16 697
Melissa Brammer United States 12 585 1.1× 148 0.5× 351 1.6× 160 0.8× 81 1.3× 36 747
Anne‐Claire Hardy‐Bessard France 16 640 1.2× 230 0.8× 206 1.0× 158 0.8× 152 2.5× 59 961
Joanna Dewar Australia 12 514 1.0× 228 0.8× 393 1.8× 68 0.3× 117 1.9× 23 970
R. Kokko Finland 12 650 1.2× 410 1.5× 163 0.8× 247 1.2× 66 1.1× 22 836
Isabelle Desmoulins France 15 361 0.7× 271 1.0× 205 1.0× 191 1.0× 84 1.4× 75 624
Roel J.W. van Kampen Netherlands 13 562 1.1× 261 0.9× 283 1.3× 75 0.4× 118 1.9× 18 891
Pavlos Papakotoulas Greece 16 777 1.5× 292 1.0× 426 2.0× 64 0.3× 144 2.4× 52 1.0k
I. Craig Henderson United States 7 903 1.7× 520 1.9× 112 0.5× 223 1.1× 216 3.5× 7 1.1k
R. Knight United Kingdom 15 367 0.7× 275 1.0× 134 0.6× 39 0.2× 66 1.1× 32 642
Stella Dolci Belgium 12 847 1.6× 488 1.7× 118 0.5× 250 1.3× 277 4.5× 27 1.1k

Countries citing papers authored by R. Asola

Since Specialization
Citations

This map shows the geographic impact of R. Asola's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Asola with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Asola more than expected).

Fields of papers citing papers by R. Asola

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Asola. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Asola. The network helps show where R. Asola may publish in the future.

Co-authorship network of co-authors of R. Asola

This figure shows the co-authorship network connecting the top 25 collaborators of R. Asola. A scholar is included among the top collaborators of R. Asola based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Asola. R. Asola is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Harmenberg, Ulrika, Timo Joensuu, Ray McDermott, et al.. (2014). Triweekly docetaxel versus biweekly docetaxel as a treatment for advanced castration resistant prostate cancer: Quality of life analysis.. Journal of Clinical Oncology. 32(4_suppl). 23–23. 2 indexed citations
2.
Kellokumpu‐Lehtinen, Pirkko‐Liisa, Ulrika Harmenberg, Timo Joensuu, et al.. (2013). 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. The Lancet Oncology. 14(2). 117–124. 135 indexed citations
3.
Kellokumpu‐Lehtinen, Pirkko, R. Asola, Liisa Elomaa, et al.. (2013). Weekly paclitaxel--an effective treatment for advanced breast cancer.. PubMed. 33(6). 2623–7. 20 indexed citations
4.
Joensuu, Heikki, Pirkko‐Liisa Kellokumpu‐Lehtinen, Riikka Huovinen, et al.. (2011). Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial. Journal of Clinical Oncology. 30(1). 11–18. 76 indexed citations
5.
Joensuu, Heikki, Liisa Sailas, Tuomo Alanko, et al.. (2009). Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial. Annals of Oncology. 21(5). 968–973. 19 indexed citations
6.
Joensuu, Heikki, Peter Bono, Vesa Kataja, et al.. (2009). S24 Update of the FINHER trial based on 5 years of follow-up. The Breast. 18. S10–S10. 5 indexed citations
7.
8.
Joensuu, Heikki, Petri Bono, Vesa Kataja, et al.. (2009). Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial. Journal of Clinical Oncology. 27(34). 5685–5692. 326 indexed citations
9.
10.
Asola, R., Heini Huhtala, & K Holli. (2006). Intensity of diagnostic and treatment activities during the end of life of patients with advanced breast cancer. Breast Cancer Research and Treatment. 100(1). 77–82. 34 indexed citations
11.
12.
Salminen, Eeva, Jussi Korpela, Marjut Varpula, et al.. (2002). Epirubicin/docetaxel regimen in progressive breast cancer—a phase II study. Anti-Cancer Drugs. 13(9). 925–929. 8 indexed citations
13.
Joensuu, Heikki, R. Asola, K Holli, et al.. (1994). Delayed diagnosis and large size of breast cancer after a false negative mammogram. European Journal of Cancer. 30(9). 1299–1302. 33 indexed citations
14.
Kujari, Harry, Heikki Joensuu, Pekka Klemi, R. Asola, & E Nordman. (1988). A flow cytometric analysis of 23 carcinoid tumors. Cancer. 61(12). 2517–2520. 18 indexed citations
15.
Joensuu, Heikki, Kerttu Irjala, & R. Asola. (1987). Serum Creatine Kinase and Lactate Dehydrogenase during Cardiac Irradiation. Acta Medica Scandinavica. 222(3). 247–250. 3 indexed citations
16.
Joensuu, Heikki, R. Asola, & Heikki Minn. (1986). Combination Chemotherapy with Dacarbazine and Lomustine in Disseminated Malignant Melanoma. Acta Radiologica Oncology. 25(3). 177–179. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Melissa Brammer Breakdown of academic impact, for papers by Anne‐Claire Hardy‐Bessard Breakdown of academic impact, for papers by Joanna Dewar Breakdown of academic impact, for papers by R. Kokko Breakdown of academic impact, for papers by Isabelle Desmoulins Breakdown of academic impact, for papers by Roel J.W. van Kampen Breakdown of academic impact, for papers by Pavlos Papakotoulas Breakdown of academic impact, for papers by I. Craig Henderson Breakdown of academic impact, for papers by R. Knight Breakdown of academic impact, for papers by Stella Dolci
Rankless by CCL
2026